NIP
CRMD icon

Nicholas Investment Partners’s CorMedix CRMD Stock Holding History

Nicholas Investment Partners’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-94,132
Closed -$762K – 201
2024
Q4 		$762K Buy
+94,132
New +$940K 0.07% 199

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Nicholas Investment Partners's CRMD Position: Q1 2025 in Review

Nicholas Investment Partners sold out of CorMedix (CRMD) in Q1 2025, closing a stake of 94,132 shares — an estimated $762K sold.

Nicholas Investment Partners first reported a position in CRMD in Q4 2024 and held it in 1 quarter. The position peaked at $762K in Q4 2024. 137 funds tracked by Wall St. Rank hold CRMD as of Q1 2025.

  • Nicholas Investment Partners reported no remaining CorMedix position as of Q1 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 94,132 CorMedix shares in Q1 2025, an estimated $762K.
  • Nicholas Investment Partners first reported a position in CorMedix in Q4 2024 and held it in 1 quarter.
  • Nicholas Investment Partners's CorMedix position peaked at $762K in Q4 2024.
  • 137 funds tracked by Wall St. Rank held CorMedix as of Q1 2025.

Based on Nicholas Investment Partners's 13F filing for Q1 2025, filed 15 May 2025.